407 results about "Hepatic disorders" patented technology

Disclosed is a diagnosis or treatment method which utilizes the content of a specific fatty acid in plasma as a marker that reflects the condition of NASH or NAFLD, or utilizes the above-mentioned content in combination with another test, another marker or the like.

The present invention provides novel pyrazolines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.

The present invention comprises compositions comprising essential oils, ginsenosides, and polysaccharides. The present invention comprises methods comprising sequential solvent extraction and polymer absorbent purification to obtain fractions comprising essential oils, ginsenosides, and polysaccharides. The compositions of the present invention may be used in forms such as tablets, gel caps, or fast-dissolve tablets for use as dietary supplements or pharmaceutical compositions. The compositions of the present invention may be used for treatment of cardiovascular diseases, neurodegenerative diseases, inflammatory diseases, hepatic disorders, viral diseases, and cancer.

Phytoceutical composition for the prevention and treatment of hepatic disorders. A specific combination of extracts of plants is taught, as well as the principles for the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.

The present invention relates to a novel tissue culture system that provides for the long term culture of proliferating hepatocytes that retain hepatic function. Disclosed are methods and compositions for ex vivo culturing of hepatocytes and nonparenchymal cells on a matrix coated with a molecule that promotes cell adhesion, proliferation or survival, in the presence of growth factors, resulting in a long-term culture of proliferating hepatocytes that retain hepatic function. The co-culturing method results in the formation of matrix/hepatic cell clusters that may be mixed with a second structured or scaffold matrix that provides a three-dimensional structural support to form structures analogous to liver tissue counterparts. The hepatic cell culture system can be used to form bio-artificial livers through which a subjects blood is perfused. Alternatively, the novel hepatic cell culture system may be implanted into the body of a recipient host having a hepatic disorder. Such hepatic disorders, include, for example, cirrhosis of the liver, induced hepatitis, chronic hepatitis, primary sclerosing cholangitis and alpha1 antitrypsin deficiency.

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:

The invention provides directional puncture sampling equipment for treating hepatopathy. The problems of low positioning precision, low puncture efficiency, inaccurate positioning and inaccurate needle insertion depth in the prior art are solved. The equipment comprises a telescopic support which is connected with an upper fixed ring. A lower fixed ring is connected with the lower part of the upper fixed ring. An outer gear ring and an inner gear ring are rotationally arranged between the upper fixed ring and the lower fixed ring. A one-way wheel is coaxially mounted on the outer gear ring. Afirst gear is mounted on the lower fixed ring. A second gear is meshed beside the first gear. The second gear is meshed with the inner gear ring. A probe mounting groove is formed in the inner gear ring. A first stop block and a second stop block are rotationally arranged on the two sides of the probe mounting groove. An arc-shaped pressing plate is mounted in the probe mounting groove. An ultrasonic probe is mounted in the probe mounting groove. A puncture needle is mounted on the rear side of the one-way wheel. According to the invention, position conversion among the ultrasonic probe, a disinfection bottle, an anesthetic needle and the puncture needle can be achieved; and liver and puncture can be positioned more accurately.

The present invention relates to the prevention and treatment of injury and diseases to the liver, biliary tract, bile ducts, gall bladder and related hepatobiliary system. Specifically, the present invention relates to methods for decreasing the action of the RON receptor tyrosine kinase in liver physiology. More specifically, the present invention relates to the use of analogs and antagonists and antibodies for inhibiting the action of the RON receptor tyrosine kinase for the prevention and treatment of liver injury or damage in acute and chronic clinical conditions.

The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating hepatic disorders such as hepatocellular carcinoma and/or cirrhosis. A variety of informative biomarkers corresponding thereto, are provided, wherein alterations in expression relative to a control is correlated with the presence of a hepatic disorder, likelihood of survival from a hepatic disorder, and likelihood of recurrence of a hepatic disorder.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:

which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

The invention provides a traditional Chinese medicine preparation for treating liver cancer, comprising the following raw medicines in parts by weight: 10-20 parts of acanthopanax, 10-20 parts of oldenlandia diffusa, 10-20 parts of radix astragali, 10-20 parts of cambogia, 10-20 parts of glossy privet fruit, 10-20 parts of white atractylodes rhizome, 10-20 parts of radix polygoni multiflori preparata, 10-20 parts of oriental wormwood, 10-20 parts of turmeric, 10-20 parts of selfheal, 10-20 parts of umbellate pore fungus, 10-20 parts of magnolia vine fruit, 10-20 parts of curcuma zedoary, 10-20 parts of tuckahoe, 10-20 parts of eclipta, 10-20 parts of root of red-rooted salvia, 10-20 parts of white peony root, 10-20 parts of barbed skullcap herb, 10-20 parts of baical skullcap root, 10-20 parts of epimedium, 1-10 parts of toad venom and 1-10 parts of scorpion. The traditional Chinese medicine preparation for treating liver cancer has the beneficial effects of prolonging the life time of inoperable patients, playing an adjuvant treating effect on patients treated mainly by operation, radiation treatment and chemo-treatment, and having certain curative effects on liver cancer-specific backgrounds of liver diseases such as hepatitis and liver cirrhosis.

The invention discloses a polyene phosphatidyl choline freeze dried injection for the treatment of hepatic diseases, which comprises polyene phosphatidyl choline as the main ingredients and pharmaceutically acceptable carrying agents, wherein the carrying agent can be auxiliary solvent selected from sodium cholate, sodium deoxycholate, sodium deoxycholate, hydroxypropyl-beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin and/or methyl cyclodextrin. The injection has higher stability.

The invention relates to a method for detecting the necrosis degree of hepatic cells through the level of plasma free DNA, and belongs to the technical field of biology. In the method, through the separation and extraction method and quantification of the plasma free DNA, the necrosis degree of the hepatic cells is reflected by the level of the free DNA. The method comprises the following steps of: preparing a primer beta-globin serving as a standard substance; extracting the plasma DNA in a plasma specimen of hepatopath; performing a real-time fluorescent quantitative polymerase chain reaction on the plasma DNA extracted in the plasma specimen; and measuring and calculating the concentration of the plasma free DNA. The method provides a new diagnostic index for the diagnosis of severe hepatitis.

The invention relates to a medicine for treating liver disease, which is made from the following raw materials comprising kudzuvine root, peppermint, white hyacinth bean, sharpleaf galangal fruit, tangerine peel, amomum fruit, pseudostellaria root, trogopterus dung, red sage root and membrane of chicken gizzard. The amomum fruit, white hyacinth bean, sharpleaf galangal fruit, tangerine peel and kudzuvine root are processed into fine powder; the peppermint is soaked to obtain a supernatant; the pseudostellaria root, the trogopterus dung, the red sage root and the membrane of chicken gizzard are added with water for decoction, cooled and filtered to obtain a filtrate; the drug dregs are added with water for another decoction, then cooled and filtered to obtain another filtrate; the filtrates are combined; the fine powder, the supernatant and the filtrates are mixed, and added with ethanol for lixiviation, thus preparing a semi-finished extractum product; then the extractum product is made into capsules or tablets or medicinal granule or aqua. The medicine has important effects of expelling the toxin and protecting the liver for chemical liver injuries which include alcohol liver injury and also liver injuries caused by medical, industrial and chemical harmful substances. The medicine has obvious curative effect on a plurality of liver diseases such as alcohol liver injury, fatty liver, hepatic cirrhosis, hepatitis, etc.

The present invention discloses a Chinese medicine compound for curing hepatic disease and a preparation method thereof. The Chinese medicine compound is made from according to milk veteh, kudzuvine root, Chinese thorowax, ganoderma, red paeonia, turtle shell, salvia miltiorrhiza, gynura segetum, canton love-pea vine and leafflower according to a certain weight portion. The present invention can be made into any common dosage form. The medicine compound provided by the present invention has the efficacy of replenishing qi and relieving liver-qi, invigorating blood circulation and softening hard masses, which is used to cure hepatitis, hepatic fibrosis, hepatocirrhosis and other hepatic diseases.

The invention discloses a traditional Chinese medicine composition for treating an autoimmune liver disease, and a preparation method thereof. The traditional Chinese medicine composition comprises the following medicinal raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-30 parts of cooked rhubarb, 10-30 parts of glossy privet fruit, 10-30 parts of radix curcumae, 10-30 parts of large-leaved gentian, 10-30 parts of caulis spatholobi, 10-30 parts of caulis sinomenii, 10-30 parts of radix rubiae, 10-30 parts of sedum sarmentosum and 5-15 parts of liquorice. The traditional Chinese medicine has the effects of strengthening body resistance, detoxifying, dispersing stagnated liver qi for promoting bile flow, promoting blood circulation to remove blood stasis, expelling wind and removing dampness; the main treatment range comprises autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and overlap syndrome of any two in the three diseases; and the traditional Chinese medicine composition has the treatment effects of restoring immune balance, inhibiting liver inflammation, protecting liver function, resisting hepatic fibrosis, improving clinical symptoms, improving survival quality and the like, and has high safety.